Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer

16 Aug 2025

Abstract excerpt

Identifying molecular drivers in triple-negative breast cancer (TNBC) is crucial. While HER2-low expression predicts response to novel antibody-drug conjugates, its biological influence on TNBC biology is unknown. We performed a comprehensive multi-omics analysis, integrating genomic, epigenomic, transcriptomic, and proteomic profiling to characterize HER2-low TNBC. We generated genome-wide DNA methylation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40817343
DOI: 10.1038/s41698-025-01023-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancerPMID 40817343Read ↗

Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment optionsSemantic proximity Read ↗

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunitiesSemantic proximity Read ↗

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesSemantic proximity Read ↗

A Comprehensive Immunologic Portrait of Triple-Negative Breast CancerSemantic proximity Read ↗

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype ShiftsSemantic proximity Read ↗

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancerSemantic proximity Read ↗

Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancerSemantic proximity Read ↗

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscapeSemantic proximity Read ↗

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer SubtypesSemantic proximity Read ↗

The DNA methylation landscape of primary triple-negative breast cancerSemantic proximity Read ↗

Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor BehaviorSemantic proximity Read ↗

Associations of TILs and genomic alterations in HER2+ early breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.